

VASTox plc
(“VASTox” or “the Company”)

**VASTOX PLC ANNOUNCES APPOINTMENT OF GEORGE ELLIOTT TO THE
BOARD OF DIRECTORS**

Oxford, UK, 23 April 2007 – VASTox plc (AIM: VOX), a leading UK biotechnology company, announces today the appointment of George Elliott to the Board of Directors as a Non-executive Director.

Mr Elliott, 54, brings to VASTox a wealth of financial and commercial expertise and experience, gained from a 30-year career during which he has overseen the financial development and growth of small technology companies into main-market FTSE listed companies.

For seven years prior to joining VASTox's Board, Mr Elliott was Chief Financial Officer of Wolfson Microelectronics plc, a leading global provider of high performance semiconductors to the consumer electronics market with blue-chip multinational customers that include Apple, Sony, Microsoft, Samsung and HP. During his period, he oversaw the Company gain an entry into the FTSE 250 index. Before his time with Wolfson, Mr Elliott was Business Development Director at McQueen International Ltd (now SYKES), where he was responsible for strategic sales and marketing.

Mr Elliott, formerly a partner of Grant Thornton, is a Chartered Accountant and has a degree in Accountancy and Finance from Heriot-Watt University.

From July 2007, one of Mr Elliott's key roles on the Board will be to Chair the Company's Audit Committee.

Barry Price, PhD, Chairman of VASTox, commented: “I am delighted to welcome a man of George's calibre to VASTox's Board of Directors. The financial knowledge he brings complements and enhances the Board's existing range of skills and expertise across all areas of business and will be invaluable as the Company enters its next phase of growth and development.”

George Elliott added “I am excited to be joining such a dynamic and ambitious company as VASTox and I look forward to playing my role in helping the Company fulfil its tremendous potential by building upon its progress already made and deliver real value to all our shareholders.”

AIM Rules Disclosure

Save for the disclosures below, there are no other disclosures to be under Rule 17 and paragraph (g) of Schedule 2 of the AIM rules.

Current Directorships

<i>Company</i>	<i>Date of Appointment</i>
Elliott Corporate Development Limited	10 April 1996

Previous Directorships

<i>Company</i>	<i>Date of Resignation</i>
Wolfson Microelectronics plc	28 February 2007

Mr Elliott was a director of Calluna Technology Limited ("CTL"), a subsidiary of Calluna plc, from 1998. He handed in his notice of resignation on 21 July 1999. In February 2000, CTL appointed an administrator. At that time CTL had external debts of £5.4 million and intergroup debts of £31.9 million.

- ends -

For more information please contact:

VASTox

Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer

Tel: +44 (0)1235 443951

Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray

Tel: +44 (0)207 638 9571

About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in both medicinal and carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 – symbol: VOX

Further information about the company is available at www.vastox.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent

uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.